Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on July 11, 2014. The report discloses the entry into a material definitive agreement regarding the expansion of the company's research and office facilities located at 840 Memorial Drive, Cambridge, Massachusetts.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only specific financial data disclosed relates to the lease amendment:
- Additional Base Rent: Approximately $513,630 over the remaining term of the lease.
- Lease Expiration: February 2016.
- Additional Expenses: The company is liable for taxes, operating expenses, and utility charges related to the new space.
Material Changes
The primary material change is the execution of the "Second Lease Amendment" with Rivertech Associates II, LLC. Key operational changes include:
- Space Expansion: Increase of approximately 8,628 square feet.
- Total Footprint: Total leased space increased from approximately 14,234 square feet to 22,862 square feet.
- Parking: Acquisition of rights to 13 additional parking spaces.
Outlook, Risks, and Management Commentary
Management intends to utilize the expansion space for office purposes. The filing notes that the company assumes additional liability for operating expenses and utilities associated with the new area. No specific forward-looking guidance, risk factors, or contingencies beyond the lease obligations are detailed in this report.
Investor Verification Checklist
- Verify the total remaining lease term to assess the annualized impact of the $513,630 rent increase.
- Review the full text of the Second Lease Amendment (Exhibit 10.1) for specific clauses regarding operating expense caps or termination rights.
- Confirm the company's current cash position to ensure it can support the increased fixed costs prior to the lease expiration in February 2016.